Adjuvant therapy in high-risk early endometrial carcinoma: a retrospective analysis of 46 cases.
10.3802/jgo.2008.19.4.236
- Author:
Jin Hwi KIM
1
;
Sung Jong LEE
;
Jeong Hoon BAE
;
Sung Ha LEE
;
Seog Nyeon BAE
;
Sung Eun NAMKOONG
;
Jong Sup PARK
Author Information
1. Division of Oncology, Department of Obstetrics and Gynecology, School of Medicine, The Catholic University of Korea, Seoul, Korea. jspark@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Endometrial carcinoma;
Adjuvant therapy;
Prognostic factor
- MeSH:
Chemotherapy, Adjuvant;
Cisplatin;
Disease-Free Survival;
Endometrial Neoplasms;
Etoposide;
Female;
Humans;
Recurrence;
Retrospective Studies
- From:Journal of Gynecologic Oncology
2008;19(4):236-240
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: We assessed the prognostic factors and the efficacy of adjuvant therapy and reviewed randomized studies carried out on patients receiving adjuvant therapy with early endometrial carcinoma. METHODS: One hundred and five patients that received primary surgical treatment for stage IB, IC and II endometrial cancer were enrolled in this study. The clinical outcomes were compared among the patients with variable prognostic factors and adjuvant treatments. RESULTS: One hundred and five patients fulfilled the eligibility criteria and 46 patients (43.8%) underwent adjuvant therapy. Disease recurrence occurred in nine patients within a median time of 24 months. Cervical involvement was an independent prognostic factor for the disease-free survival rates. Eight of 16 patients with FIGO stage II disease received adjuvant chemotherapy consisting of cisplatin and etoposide (or cyclophosphamide) or combined chemoradiation. The 5-year disease-free survival rate for these patients was 87.5%, a value significantly higher than for patients that received radiation therapy alone (30%). CONCLUSION: Adjuvant chemotherapy or combination chemo-radiotherapy might be superior to radiation therapy alone in high-risk early endometrial cancer patients.
